Abstract
MPN-498 Addition of Navitoclax to Ruxolitinib for Myelofibrosis Patients With Relapsed/Refractory Disease and Suboptimal Response to Ruxolitinib Monotherapy: REFINE Cohort 1 Dose Escalation and Expansion
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have